Why the study?
Does amyloid subtype (AL vs ATTR) affect 3-year all-cause mortality in patients with cardiac amyloidosis?
Population
360 patients at the time of initial diagnosis of cardiac amyloidosis (191 AL and 169 ATTR) from 2002 to 2014
Comparison
Light chain (AL) amyloidosis subtype vs Transthyretin (ATTR) amyloidosis subtype
Design
Cohort
Follow-up
3 years
Authors
Loading...
AL subtype signals highest mortality risk in cardiac amyloidosis; supports risk stratification but leaves open causal and therapeutic implications.
Does amyloid subtype (AL vs ATTR) affect 3-year all-cause mortality in patients with cardiac amyloidosis?
AL cardiac amyloidosis is associated with a significantly higher 3-year all-cause mortality compared to ATTR amyloidosis, independent of clinical, morphological, and biomarker covariates.
Sperry et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: